Nu-Med Plus Announces Investigational Study of Stored Blood as a New Path for Their NO Devices

SALT LAKE CITY, UT--(Marketwired - May 10, 2016) - Nu-Med Plus, Inc. (OTCBB: NUMD), a medical device development company, announces they are embarking on a new investigational study applying their patent pending nitric oxide delivery devices to the protection of stored blood. Prior investigation studies have shown that adding nitric oxide to stored blood has several beneficial effects that could lead to a better stored blood product. Management has identified the estimated $4 billion dollar US blood market as a strategic product development project that will add significant value to Nu-Med.

Nitric oxide is a medically essential gas that is presently used in Neonate Hypoxia therapy and may have future applications for a variety of other diseases and complications that are currently being investigated. Jeff Robins, President and CEO of Nu-Med Plus, Inc. commented, "We have realized our systems are not restricted to the pulmonary arena. This study may give us the opportunity to expand the direction of our products into other applications."

About Nu-Med Plus, Inc.

Nu-Med Plus, Inc. is a medical device development company created to explore medical applications of newly developed technologies. The strategy is to focus on high growth potential markets where there is a clearly defined need recognized by the medical community that can be addressed by Nu-Med Plus and its technical expertise. Initial research and product development has been in the delivery of nitric oxide gas for therapeutic use. For more company information please visit www.nu-medplus.com.

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's ability to complete proposed private placement financing. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.